Global Information
회사소개 | 문의 | 위시리스트

인공호흡기 관련 폐렴(VAP) : 파이프라인 리뷰

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019

리서치사 Global Markets Direct
발행일 2019년 02월 상품 코드 264097
페이지 정보 영문 147 Pages
가격
US $ 2,000 ₩ 2,308,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,616,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,924,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


인공호흡기 관련 폐렴(VAP) : 파이프라인 리뷰 Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019
발행일 : 2019년 02월 페이지 정보 : 영문 147 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

인공호흡기 관련 폐렴(VAP)은 기관 내 삽관과 기관개구를 통한 인공호흡기 장착 후 48시간 이후에 발병하는 폐렴으로, 하기도와 폐질로의 미생물 침입이 원인입니다. 가장 중요한 증상은 열, 저체온증, 고름성 가래, 저산소혈증입니다.

인공호흡기 관련 폐렴(VAP : Ventilator Associated Pneumonia)의 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 치료제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

목차

서론

인공호흡기 관련 폐렴(VAP) 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

개발중인 치료제 : 기업별

조사중인 치료제 : 대학/연구기관별

파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품
  • 개발 단계가 불명인 제품

개발중인 제품 : 기업별

조사중인 제품 : 대학/연구기관별

치료제 개발에 참여하고 있는 기업

  • Achaogen Inc.
  • Adenium Biotech ApS
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • Cardeas Pharma Corp.
  • MedImmune, LLC
  • Meiji Seika Pharma Co., Ltd.
  • Merck & Co., Inc.
  • Motif Bio Plc
  • Nabriva Therapeutics AG
  • Savara Inc.
  • Tetraphase Pharmaceuticals Inc.

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개요

  • (amikacin + fosfomycin)
  • (avibactam + ceftazidime)
  • (ceftolozane sulfate + tazobactam sodium)
  • (cilastatin sodium + imipenem + relebactam)
  • (Pseudomonas + ventilator associated pneumonia) vaccine
  • AA-139
  • Aerucin
  • arbekacin
  • eravacycline
  • fosfomycin tromethamine
  • iclaprim mesylate
  • lefamulin acetate
  • MEDI-4893
  • Nu-2
  • Panaecin
  • panobacumab
  • plazomicin sulfate
  • Qn-2251
  • tedizolid phosphate
  • tosatoxumab
  • vancomycin hydrochloride

파이프라인 제품의 최신 동향

휴지중인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주목 정보와 프레스 릴리스

부록

도표

KSM 16.04.25

List of Tables

  • Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals Inc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca Plc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Cumberland Pharmaceuticals Inc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by CytaCoat AB, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Destiny Pharma Plc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Evaxion Biotech ApS, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by MedImmune LLC, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co Inc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Motif Bio Plc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics Plc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Polyphor AG, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Shionogi & Co Ltd, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Spero Therapeutics Inc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Wockhardt Ltd, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Dormant Projects, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019, provides an overview of the Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline landscape.

Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 4, 8, 8, 1 and 1 respectively.

Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Ventilator Associated Pneumonia (VAP) - Overview
  • Ventilator Associated Pneumonia (VAP) - Therapeutics Development
  • Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment
  • Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development
  • Ventilator Associated Pneumonia (VAP) - Drug Profiles
  • Ventilator Associated Pneumonia (VAP) - Dormant Projects
  • Ventilator Associated Pneumonia (VAP) - Discontinued Products
  • Ventilator Associated Pneumonia (VAP) - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q
 
BCC Research